GTC Biotherapeutics (fka GTCB)

[exwannabe]

At N=50 (in the subgroup), the lack of stat sig. mortality is not surpising, but the overall DIC benifit looked promising.

Question, since ART-123 works on the APC pathway would this be expected to behave similarly to Xigris (recmbinant APC)?